| Abstract: |
Two decades ago, the overexpression of P-glycoprotein (Pgp) was first demonstrated to mediate the energy-dependent efflux of a variety of chemotherapeutic agents from tumor cells, resulting in the development of multidrug resistance (MDR). Not surprisingly, this discovery triggered an ongoing search for agents that would inhibit Pgp function, with the hope that by doing so the MDR phenotype could be reversed. As our understanding of Pgp function and pharmacokinetics has increased, this quest has become more urgent, as well as more complex. |
| Keywords: |
genetics; review; animal; metabolism; animals; biological model; models, biological; alkylating agent; genetic transcription; transcription, genetic; drug effect; drug resistance; drug resistance, neoplasm; chemistry; antineoplastic agents, alkylating; forecasting; chemical structure; molecular structure; trabectedin; multidrug resistance; p-glycoprotein; drug resistance, multiple; isoquinoline derivative; glycoprotein p; dioxoles; isoquinolines; tetrahydroisoquinolines; tetrahydroisoquinoline derivative; 1,3 dioxolane derivative; humans; human
|
